The collaborative work by Investigators from BRFAA, the Tamvakopoulos team (T Karampelas, E Skavatsou and A Velentza-Albani) with Professor V Sarli’s Medicinal Chemistry team from the Aristotle University of Thessaloniki and F Bianchini from the University of Florence describe the design, synthesis and pharmacological evidence that novel analogues of gemcitabine (GEM), can be used for the targeted delivery of GEM to integrin overexpressing cancer cells. Such strategies are important for the treatment of solid tumors since they can increase tumor delivery of GEM, minimize common side effects associated with treatment and increase the stability of the therapeutic.
Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine
Chatzisideri T, Leonidis G, Karampelas T, Skavatsou E, Velentza-Almpani A, Bianchini F, Tamvakopoulos C *, Sarli V *. J Med Chem. 2021 Dec 30. doi: 10.1021/acs.jmedchem.1c01468. Online ahead of print. PMID: 34967607